Brokerages expect that Celldex Therapeutics, Inc. (NASDAQ:CLDX) will post earnings of ($0.12) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Celldex Therapeutics’ earnings, with estimates ranging from ($0.17) to ($0.07). Celldex Therapeutics reported earnings per share of ($0.14) during the same quarter last year, which suggests a positive year over year growth rate of 14.3%. The company is scheduled to announce its next quarterly earnings report on Tuesday, November 6th.
According to Zacks, analysts expect that Celldex Therapeutics will report full year earnings of ($1.15) per share for the current financial year, with EPS estimates ranging from ($1.26) to ($1.06). For the next year, analysts anticipate that the business will post earnings of ($0.53) per share, with EPS estimates ranging from ($0.72) to ($0.26). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Celldex Therapeutics.
Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.03. Celldex Therapeutics had a negative return on equity of 47.40% and a negative net margin of 1,159.26%. The company had revenue of $2.76 million for the quarter, compared to analyst estimates of $2.70 million.
CLDX stock traded down $0.01 during mid-day trading on Friday, hitting $0.44. The stock had a trading volume of 2,406,200 shares, compared to its average volume of 2,238,955. Celldex Therapeutics has a 1-year low of $0.40 and a 1-year high of $3.09. The firm has a market cap of $73.26 million, a P/E ratio of -0.55 and a beta of 2.29.
Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. increased its holdings in shares of Celldex Therapeutics by 1.7% during the 1st quarter. BlackRock Inc. now owns 10,097,481 shares of the biopharmaceutical company’s stock valued at $23,527,000 after acquiring an additional 166,780 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Celldex Therapeutics by 74.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 4,167,585 shares of the biopharmaceutical company’s stock valued at $9,710,000 after acquiring an additional 1,783,765 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Celldex Therapeutics by 27.7% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 900,185 shares of the biopharmaceutical company’s stock valued at $453,000 after acquiring an additional 195,147 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of Celldex Therapeutics during the 2nd quarter valued at about $322,000. Finally, Acadian Asset Management LLC increased its holdings in shares of Celldex Therapeutics by 378.4% during the 2nd quarter. Acadian Asset Management LLC now owns 1,157,880 shares of the biopharmaceutical company’s stock valued at $583,000 after acquiring an additional 915,863 shares during the last quarter. 33.54% of the stock is currently owned by institutional investors and hedge funds.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma.
Featured Article: Marijuana Stocks Investing Considerations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.